Wednesday, April 6, 2011

High plasma concentrations of chemokine CXCL10 predict poor treatment responses in chronic HCV infection

Jane Bradbury, The Lancet Infectious Diseases, Volume 11, Issue 2, Page 89, February 2011:

The current treatment for chronic hepatitis C virus (HCV) infection—pegylated interferon and ribavirin—is effective in less than half of patients infected with HCV genotypes 1 or 4.

Paradoxically, high plasma concentrations of the proinflammatory chemokine CXCL10 predict poor treatment responses.

A new study provides an explanation for this paradox by showing that CXCL10 in the plasma of non-responding patients exists as an amino-terminal truncated antagonist form that is ge ... The Lancet: To read this article in full you will need to login or make a payment

No comments:


Related Posts with Thumbnails